- Home
- SISI vs CMND Comparison
SISI vs CMND Comparison
Compare SISI & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SISI
- CMND
- Stock Information
- Founded
- SISI 1997
- CMND 2017
- Country
- SISI China
- CMND Canada
- Employees
- SISI N/A
- CMND N/A
- Industry
- SISI Medicinal Chemicals and Botanical Products
- CMND Biotechnology: Pharmaceutical Preparations
- Sector
- SISI Health Care
- CMND Health Care
- Exchange
- SISI Nasdaq
- CMND Nasdaq
- Market Cap
- SISI 5.6M
- CMND 5.3M
- IPO Year
- SISI 2016
- CMND N/A
- Fundamental
- Price
- SISI $5.60
- CMND $0.97
- Analyst Decision
- SISI
- CMND
- Analyst Count
- SISI 0
- CMND 0
- Target Price
- SISI N/A
- CMND N/A
- AVG Volume (30 Days)
- SISI 97.6K
- CMND 2.0M
- Earning Date
- SISI 11-13-2025
- CMND 09-11-2025
- Dividend Yield
- SISI N/A
- CMND N/A
- EPS Growth
- SISI N/A
- CMND N/A
- EPS
- SISI N/A
- CMND N/A
- Revenue
- SISI $9,601,324.00
- CMND N/A
- Revenue This Year
- SISI N/A
- CMND N/A
- Revenue Next Year
- SISI N/A
- CMND N/A
- P/E Ratio
- SISI N/A
- CMND N/A
- Revenue Growth
- SISI 1133.26
- CMND N/A
- 52 Week Low
- SISI $1.00
- CMND $0.80
- 52 Week High
- SISI $271.50
- CMND $2.18
- Technical
- Relative Strength Index (RSI)
- SISI 43.37
- CMND 41.98
- Support Level
- SISI $5.42
- CMND $0.98
- Resistance Level
- SISI $6.27
- CMND $1.05
- Average True Range (ATR)
- SISI 0.61
- CMND 0.07
- MACD
- SISI -0.04
- CMND -0.01
- Stochastic Oscillator
- SISI 12.49
- CMND 12.72
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.